These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23678001)

  • 1. Identification of a highly conserved surface on Tat variants.
    Mediouni S; Darque A; Ravaux I; Baillat G; Devaux C; Loret EP
    J Biol Chem; 2013 Jun; 288(26):19072-80. PubMed ID: 23678001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade.
    Mediouni S; Watkins JD; Pierres M; Bole A; Loret EP; Baillat G
    J Biol Chem; 2012 Apr; 287(15):11942-50. PubMed ID: 22362765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography.
    Serrière J; Dugua JM; Bossus M; Verrier B; Haser R; Gouet P; Guillon C
    J Mol Biol; 2011 Jan; 405(1):33-42. PubMed ID: 21035463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.
    Watkins JD; Lancelot S; Campbell GR; Esquieu D; de Mareuil J; Opi S; Annappa S; Salles JP; Loret EP
    Retrovirology; 2006 Jan; 3():8. PubMed ID: 16441880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants.
    Opi S; Péloponèse JM; Esquieu D; Campbell G; de Mareuil J; Walburger A; Solomiac M; Grégoire C; Bouveret E; Yirrell DL; Loret EP
    J Biol Chem; 2002 Sep; 277(39):35915-9. PubMed ID: 12080071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homonuclear 1H NMR and circular dichroism study of the HIV-1 Tat Eli variant.
    Watkins JD; Campbell GR; Halimi H; Loret EP
    Retrovirology; 2008 Sep; 5():83. PubMed ID: 18808674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 infected patients have antibodies recognizing folded Tat.
    Mediouni S; Baillat G; Darque A; Ravaux I; Loret E
    Infect Disord Drug Targets; 2011 Feb; 11(1):57-63. PubMed ID: 21303342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full-length HIV-1 Tat protein necessary for a vaccine.
    Opi S; Péloponèse JM; Esquieu D; Watkins J; Campbell G; De Mareuil J; Jeang KT; Yirrell DL; Kaleebu P; Loret EP
    Vaccine; 2004 Aug; 22(23-24):3105-11. PubMed ID: 15297062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UV and X-ray structural studies of a 101-residue long Tat protein from a HIV-1 primary isolate and of its mutated, detoxified, vaccine candidate.
    Foucault M; Mayol K; Receveur-Bréchot V; Bussat MC; Klinguer-Hamour C; Verrier B; Beck A; Haser R; Gouet P; Guillon C
    Proteins; 2010 May; 78(6):1441-56. PubMed ID: 20034112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zn2+ binding to cysteine-rich domain of extracellular human immunodeficiency virus type 1 Tat protein is associated with Tat protein-induced apoptosis.
    Misumi S; Takamune N; Ohtsubo Y; Waniguchi K; Shoji S
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):297-304. PubMed ID: 15117453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tat-neutralizing antibodies in vaccinated macaques.
    Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
    J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 10E8-like neutralizing antibodies against HIV-1 induced using a precisely designed conformational peptide as a vaccine prime.
    Yu Y; Tong P; Li Y; Lu Z; Chen Y
    Sci China Life Sci; 2014 Jan; 57(1):117-27. PubMed ID: 24369352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?
    Campbell GR; Loret EP
    Retrovirology; 2009 May; 6():50. PubMed ID: 19467159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans-cellular trans-activation.
    Valvatne H; Szilvay AM; Helland DE
    AIDS Res Hum Retroviruses; 1996 May; 12(7):611-9. PubMed ID: 8743086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile.
    Kashi VP; Jacob RA; Shamanna RA; Menon M; Balasiddaiah A; Varghese RK; Bachu M; Ranga U
    PLoS One; 2014; 9(12):e114155. PubMed ID: 25531437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Furin cleavage of the HIV-1 Tat protein.
    Tikhonov I; Ruckwardt TJ; Berg S; Hatfield GS; David Pauza C
    FEBS Lett; 2004 May; 565(1-3):89-92. PubMed ID: 15135058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
    McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
    Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting.
    Goldstein G; Chicca JJ
    Vaccine; 2010 Jan; 28(4):1008-14. PubMed ID: 19931501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR.
    Tosi G; Meazza R; De Lerma Barbaro A; D'Agostino A; Mazza S; Corradin G; Albini A; Noonan DM; Ferrini S; Accolla RS
    Eur J Immunol; 2000 Apr; 30(4):1120-6. PubMed ID: 10760801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.